Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 23, 2026British Journal of HaematologyOpen Access

Adjusted delivery, stronger outcomes: Selinexor therapeutic adaptation and positioning in previously treated multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

MBMuhamed Baljević

Discussion

Loading...

Member takes

Overview

Randomized trial shows enhanced efficacy and tolerability outcomes in previously treated multiple myeloma, suggesting dose adjustment benefits.

Key Points

  • To evaluate the impact of selinexor dose reduction on outcomes in patients with lenalidomide-refractory multiple myeloma.
  • Subgroup analysis of the BOSTON trial focusing on lenalidomide-refractory multiple myeloma patients
  • Comparison of selinexor dose reduction versus full dosing
  • Assessment of efficacy outcomes, tolerability, and quality of life metrics
  • Dose reduction of selinexor led to an overall response rate of 74.3% compared to 55.6% with full dose (p<0.0001)
  • Improved duration of response to 15.3 months versus 4.2 months
  • Significantly improved quality of life as assessed by a 10-point improvement threshold.

Cite This Study

Muhamed Baljević (2026) studied this question.

synapsesocial.com/papers/6a61afe0faa9903c5116a9b6https://doi.org/10.1111/bjh.70711
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide‐refractory multiple myeloma: Subgroup analysis of the <scp>BOSTON</scp> trial2026 · 1 citations
  2. 2Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: Extended follow‐up subgroup analysis of the <scp>BOSTON</scp> trial2024 · 13 citations
  3. 3Selinexor in combination with dexamethasone with or without bortezomib in heavily pretreated multiple myeloma: A case series2024 · 1 citations
  4. 4Primary analysis of the phase 3 randomized trial of selinexor and lenalidomide versus lenalidomide alone as maintenance therapy post autologous stem cell transplant for patients with newly diagnosed multiple myeloma (ALLG MM23; SEALAND)2025
  5. 5Lower dose and weekly schedules of selinexor in multiple myeloma - updated evidence on safety and efficacy2025